Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848 · see citing works

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

Smith, S. C., Allen, J. K., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Krumholz, H. M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174516 · Cited by 2,088 · see citing works

Intensive Lifestyle Changes for Reversal of Coronary Heart Disease

Ornish, D. (1998) · JAMA · doi:10.1001/jama.280.23.2001 · Cited by 1,730 · see citing works

GSRS—A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease

Svedlund, J., Sjödin, I., & Dotevall, G. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01535722 · Cited by 1,319 · see citing works

The Effects of Low-Carbohydrate versus Conventional Weight Loss Diets in Severely Obese Adults: One-Year Follow-up of a Randomized Trial

Stern, L., Iqbal, N., Seshadri, P., Chicano, K. L., Daily, D. A., McGrory, J., Williams, M., Gracely, E. J., & Samaha, F. F. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-10-200405180-00007 · Cited by 831 · see citing works

The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial

Stem, L., Iqbal, N., Seshadri, P., & Chicano, K. L. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.07.103 · Cited by 629 · see citing works

Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease

Revicki, D. A., Wood, M., Wiklund, I. E., & Crawley, J. A. (1997) · Quality of Life Research · doi:10.1023/a:1008841022998 · Cited by 623 · see citing works

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580 · see citing works

Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia

Sharp, D., Blinderman, L., Combs, K. A., Kienzle, B. K., Ricci, B., Wager‐Smith, K., Gil, C. M., Turck, C. W., Boumas, M.-E., Rader, D. J., et al. (1993) · Nature · doi:10.1038/365065a0 · Cited by 501 · see citing works

Risk for Myopathy With Statin Therapy in High-Risk Patients

Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 452 · see citing works

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

Knopp, R. H. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00807-2 · Cited by 401 · see citing works

Hepatic Niemann-Pick C1–like 1 regulates biliary cholesterol concentration and is a target of ezetimibe

Temel, R. E., Tang, W., Ma, Y., Rudel, L. L., Willingham, M. C., Ioannou, Y. A., Davies, J. P., Nilsson, L.-M., & Yu, L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30060 · Cited by 368 · see citing works

An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits

Wetterau, J. R., Gregg, R. E., Harrity, T. W., ARBEENY, C. M., Cap, M., Connolly, F., Chu, C.-H., George, R. J., Gordon, D. A., Jamil, H., et al. (1998) · Science · doi:10.1126/science.282.5389.751 · Cited by 266 · see citing works

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study

Ballantyne, C. M., Abate, N. I., Yuan, Ž., King, T. R., & Palmisano, J. J. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.11.023 · Cited by 238 · see citing works

Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins

Andrews, T. C., Ballantyne, C. M., Hsia, J. A., & Kramer, J. H. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00799-9 · Cited by 178 · see citing works

CP-346086

Chandler, C. E., Wilder, D. E., Pettini, J. L., Savoy, Y. E., Petras, S. F., Chang, G., Vincent, J., & Harwood, H. J. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300094-jlr200 · Cited by 177 · see citing works

The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups

GLOBE, D. R., Bayliss, M. S., & Harrison, D. J. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-62 · Cited by 148 · see citing works

Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER

Liao, W., Hui, T. Y., Young, S. G., & Davis, R. A. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300020-jlr200 · Cited by 113 · see citing works

Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease

Rader, D. J. (1993) · JAMA · doi:10.1001/jama.270.7.865 · Cited by 104 · see citing works

Abetalipoproteinemia

Rader, D. J. (1993) · JAMA · doi:10.1001/jama.1993.03510070087042 · Cited by 97 · see citing works

Comparative Evaluation of Fecal Fat Excretion Induced by Orlistat and Chitosan

Guerciolini, R., Radu‐Radulescu, L., Boldrin, M. N., Dallas, J., & Moore, R. (2001) · Obesity Research · doi:10.1038/oby.2001.47 · Cited by 77 · see citing works

MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?

Burnett, J. R., & Watts, G. F. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.181 · Cited by 58 · see citing works

Psychometric validation of the German translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux disease.

Kulich, K. R., Malfertheiner, P., Madisch, A., Labenz, J., Bayerdörffer, E., Miehlke, S., Carlsson, J., & Wiklund, I. K. (2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-62 · Cited by 56 · see citing works

Lipid-lowering effects of statins: a comparative review

Davidson, M. H., & Robinson, J. G. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.13.1701 · Cited by 51 · see citing works

In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism

Ikewaki, K., Rader, D. J., Zech, L. A., & Brewer, H. B. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39776-5 · Cited by 39 · see citing works

Adverse Events With Concomitant Amiodarone and Statin Therapy

Alsheikh-Ali, A. A. A., & Karas, R. H. (2005) · Preventive Cardiology · doi:10.1111/j.1520-037x.2005.4060.x · Cited by 31 · see citing works

Implitapide

Sorbera, L. A., Martin, L., Silvestre, J. S., & Castañer, J. (2000) · Drugs of the Future · doi:10.1358/dof.2000.025.11.599755 · Cited by 13 · see citing works

BAY 13-9952 (Implitapide), an inhibitor of the microsomal triglyceride transfer protein (MTP), inhibits atherosclerosis and prolongs lifetime in apo-E knockout mice

Zaiss, S., & Sander, E. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)80611-5 · Cited by 4 · see citing works

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M., Cromwell, W. C., Lachmann, R., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 921 · see citing works

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017

Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813 · see citing works

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744 · see citing works

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 575 · see citing works

Lipoprotein(a): resurrected by genetics

Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521 · see citing works

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Raal, F. J., Scott, R. C., Somaratne, R. M., Bridges, I. M., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 502 · see citing works

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

Stein, E. A., Honarpour, N., Wasserman, S. M., Xu, F., Scott, R. C., & Raal, F. J. (2013) · Circulation · doi:10.1161/circulationaha.113.004678 · Cited by 330 · see citing works

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 317 · see citing works

MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion

Soh, J., Iqbal, J., Queiroz, J., Fernandez-Hernando, C. F., & Hussain, M. M. (2013) · Nature Medicine · doi:10.1038/nm.3200 · Cited by 301 · see citing works

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia

Stein, E. A., Dufour, R., Gagné, C., Gaudet, D., East, C. A., Donovan, J. M., Chin, W., Tribble, D. L., & McGowan, M. P. (2012) · Circulation · doi:10.1161/circulationaha.112.104125 · Cited by 297 · see citing works

Lipid management in patients with chronic kidney disease

Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 275 · see citing works

Lomitapide and Mipomersen

Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264 · see citing works

Genetic determinants of plasma triglycerides

Johansen, C. T., Kathiresan, S., & Hegele, R. A. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r009720 · Cited by 258 · see citing works

Multiple functions of microsomal triglyceride transfer protein

Hussain, M. M., Rava, P., Walsh, M. T., Rana, M., & Iqbal, J. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-14 · Cited by 261 · see citing works

Reversal of Hyperlipidemia With a Genetic Switch Favorably Affects the Content and Inflammatory State of Macrophages in Atherosclerotic Plaques

Feig, J. E., Parathath, S., Rong, J. X., Mick, S. L., Vengrenyuk, Y., Grauer, L., Young, S. G., & Fisher, E. A. A. (2011) · Circulation · doi:10.1161/circulationaha.110.984146 · Cited by 236 · see citing works

Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases

Kronenberg, F. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6648-3 · Cited by 227 · see citing works

New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes

Sahebkar, A., & Watts, G. F. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.019 · Cited by 181 · see citing works

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

Akdim, F., Visser, M. E., Tribble, D. L., Baker, B. F., Stroes, E. S. G., Yu, R. Z., Flaim, J., Su, J. Q., Stein, E. A., & Kastelein, J. J. P. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.01.003 · Cited by 178 · see citing works

The Severe Hypercholesterolemia Phenotype

Sniderman, A. D., Tsimikas, S., & Fazio, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.060 · Cited by 177 · see citing works

New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

Sahebkar, A., & Watts, G. F. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6479-4 · Cited by 176 · see citing works

Recent advances in pharmacotherapy for hypertriglyceridemia

Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 166 · see citing works

Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)

Tsimikas, S., Moriarty, P. M., & Stroes, E. S. G. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.051 · Cited by 155 · see citing works

Genetic determinants of hepatic steatosis in man

Hooper, A. J., Adams, L. A., & Burnett, J. R. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r008896 · Cited by 142 · see citing works

Gut-liver interaction in triglyceride-rich lipoprotein metabolism

Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 126 · see citing works

The Impact of Egg Nutrient Composition and Its Consumption on Cholesterol Homeostasis

Kuang, H., Yang, F., Zhang, Y., Wang, T., & Chen, G. (2018) · Cholesterol · doi:10.1155/2018/6303810 · Cited by 128 · see citing works

Severe Hypertriglyceridemia With Pancreatitis

Sacks, F. M., Stanesa, M., & Hegele, R. A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.13309 · Cited by 119 · see citing works

Pharmacological strategies for lowering LDL cholesterol: statins and beyond

Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 114 · see citing works

Lipoprotein(a): more interesting than ever after 50 years

Dubé, J. B., Boffa, M. B., Hegele, R. A., & Koschinsky, M. L. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835111d8 · Cited by 105 · see citing works

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs

Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99 · see citing works

Current therapies for lowering lipoprotein (a)

van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. S. G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 96 · see citing works

The degradation of apolipoprotein B100: Multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways

Fisher, E. A. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.02.001 · Cited by 93 · see citing works

Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assemblyThis paper is one of a selection of papers published in this special issue entitled “Canadian Society of Biochemistry, Molecular & Cellular Biology 52nd Annual Meeting — Protein Folding: Principles and Diseases” and has undergone the Journal's usual peer review process.

Rutledge, A. C., Su, Q., & Adeli, K. (2010) · Biochemistry and Cell Biology · doi:10.1139/o09-168 · Cited by 91 · see citing works

Lipoprotein(a): A missing culprit in the management of athero‐thrombosis?

Ferretti, G., Bacchetti, T., Johnston, T. P., Banach, M., Pirro, M., & Sahebkar, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26050 · Cited by 92 · see citing works

Contemporary Aspects of the Biology and Therapeutic Regulation of the Microsomal Triglyceride Transfer Protein

Hooper, A. J., Burnett, J. R., & Watts, G. F. (2014) · Circulation Research · doi:10.1161/circresaha.116.304637 · Cited by 85 · see citing works

Mipomersen, an antisense apolipoprotein B synthesis inhibitor

Bell, D. A., Hooper, A. J., & Burnett, J. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.547471 · Cited by 84 · see citing works

<p>Lomitapide: a review of its clinical use, efficacy, and tolerability</p>

Alonso, R., Cuevas, A., & Mata, P. (2019) · Core Evidence · doi:10.2147/ce.s174169 · Cited by 81 · see citing works

Regulation of chylomicron production in humans

Xiao, C., & Lewis, G. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.019 · Cited by 77 · see citing works

New approaches to target microsomal triglyceride transfer protein

Hussain, M. M., & Bakillah, A. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328312707c · Cited by 78 · see citing works

Lomitapide for the treatment of hypercholesterolemia

Berberich, A. J., & Hegele, R. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340941 · Cited by 77 · see citing works

The renaissance of lipoprotein(a): Brave new world for preventive cardiology?

Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 71 · see citing works

Lapaquistat Acetate

Stein, E. A., Bays, H. E., O’Brien, D., Pedicano, J., Piper, E., & Spezzi, A. (2011) · Circulation · doi:10.1161/circulationaha.110.975284 · Cited by 70 · see citing works

Cholesterol Metabolism: A Double-Edged Sword in Hepatocellular Carcinoma

Zhou, F., & Sun, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.762828 · Cited by 66 · see citing works

Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies

Bhatia, H. S., & Wilkinson, M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206040 · Cited by 64 · see citing works

New lipid-lowering drugs: an update

Wierzbicki, A. S., Hardman, T. C., & Viljoen, A. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02867.x · Cited by 65 · see citing works

Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials

Șerban, M.-C., Sahebkar, A., Mikhailidis, D. P., Toth, P. P., Jones, S. R., Muntner, P., Blaha, M. J., Andrica, F., Martin, S. S., Borza, C., et al. (2016) · Scientific Reports · doi:10.1038/srep19188 · Cited by 65 · see citing works

Microsomal transfer protein inhibition in humans

Cuchel, M., & Rader, D. J. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32836139df · Cited by 63 · see citing works

Emerging therapeutic agents to lower lipoprotein (a) levels

Kolski, B. C., & Tsimikas, S. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283598d81 · Cited by 63 · see citing works

Control of chylomicron export from the intestine

Mansbach, C. M., & Siddiqi, S. A. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00228.2015 · Cited by 61 · see citing works

Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target

Fusco, S. A. D., Arca, M., Scicchitano, P., Alonzo, A., Perone, F., Gulizia, M. M., Gabrielli, D., Oliva, F. G., Imperoli, G., & Colivicchi, F. (2022) · Heart · doi:10.1136/heartjnl-2021-320708 · Cited by 61 · see citing works

Microsomal Triglyceride Transfer Protein Inhibition Induces Endoplasmic Reticulum Stress and Increases Gene Transcription via Ire1α/cJun to Enhance Plasma ALT/AST

Josekutty, J., Iqbal, J., Iwawaki, T., Kohno, K., & Hussain, M. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.459602 · Cited by 59 · see citing works

MicroRNA-30c Mimic Mitigates Hypercholesterolemia and Atherosclerosis in Mice

Irani, S., Pan, X., Peck, B. C. E., Iqbal, J., Sethupathy, P., & Hussain, M. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.728451 · Cited by 57 · see citing works

Insights from human congenital disorders of intestinal lipid metabolism

Levy, E. H. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r052415 · Cited by 56 · see citing works

Allelic and phenotypic spectrum of plasma triglycerides

Johansen, C. T., & Hegele, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.007 · Cited by 56 · see citing works

An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias

Rached, F. H., Chapman, M. J., & Kontush, A. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.85 · Cited by 54 · see citing works

Molecular pathways and agents for lowering LDL-cholesterol in addition to statins

Costet, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.006 · Cited by 53 · see citing works

New Frontiers in Lp(a)-Targeted Therapies

Borrelli, M. J., Youssef, A., Boffa, M. B., & Koschinsky, M. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.004 · Cited by 53 · see citing works

Lipoprotein(a)

Kronenberg, F. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_504 · Cited by 53 · see citing works

Combination therapy in dyslipidemia: Where are we now?

Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 52 · see citing works

Current Options and Future Perspectives in the Treatment of Dyslipidemia

Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 52 · see citing works

Role of microRNA-30c in lipid metabolism, adipogenesis, cardiac remodeling and cancer

Irani, S., & Hussain, M. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000162 · Cited by 50 · see citing works

Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – Some answers and still many questions

Kotani, K., Șerban, M.-C., Penson, P. E., Lippi, G., & Banach, M. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2016.1188055 · Cited by 50 · see citing works

Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis

Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 51 · see citing works

Lipoprotein(a) and cardiovascular disease

Boffa, M. B., & Koschinsky, M. L. (2024) · Biochemical Journal · doi:10.1042/bcj20240037 · Cited by 47 · see citing works

Host-targeting therapies for hepatitis C virus infection: current developments and future applications

Crouchet, É., Wrensch, F., Schuster, C., Zeisel, M. B., & Baumert, T. F. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818759483 · Cited by 47 · see citing works

Dietary natural products as emerging lipoprotein(a)‐lowering agents

Momtazi‐Borojeni, A. A., Katsiki, N., Pirro, M., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28134 · Cited by 46 · see citing works

Familial Hypercholesterolemia: Present and Future Management

Sjouke, B., Kusters, D. M., Kastelein, J. J. P., & Hovingh, G. K. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0219-9 · Cited by 44 · see citing works

Pharmacotherapies for lipid modification: beyond the statins

Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 44 · see citing works

A Small-Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein, SLx-4090: Biochemical, Pharmacodynamic, Pharmacokinetic, and Safety Profile

Kim, E., Campbell, A. S., Schueller, O. J. A., Wong, E., Cole, B., Kuo, J. J., Ellis, J. L., Ferkany, J. W., & Sweetnam, P. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.177527 · Cited by 42 · see citing works

New Therapies for Reducing Low-Density Lipoprotein Cholesterol

Stein, E. A., & Raal, F. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.008 · Cited by 42 · see citing works

Novel nonstatin strategies to lower low-density lipoprotein cholesterol

Davidson, M. H. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0011-0 · Cited by 38 · see citing works

Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia

Tuteja, S., Duffy, D., Dunbar, R. L., Movva, R., Gadi, R., Bloedon, L. T., & Cuchel, M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1351 · Cited by 36 · see citing works

New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review

Merćep, I., Strikić, D., Slišković, A. M., & Reiner, Ž. (2022) · Pharmaceuticals · doi:10.3390/ph15070839 · Cited by 37 · see citing works

Statin Intolerance: Diagnosis and Remedies

Pirillo, A., & Catapano, A. L. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0582-z · Cited by 35 · see citing works

Lomitapide: A Review of its Use in Adults with Homozygous Familial Hypercholesterolemia

Perry, C. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0030-7 · Cited by 35 · see citing works

Atherosclerosis: Recent trials, new targets and future directions

Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 34 · see citing works

Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development

Stein, E. A. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.011 · Cited by 34 · see citing works

Diagnosis and treatment of severe hypertriglyceridemia

Viljoen, A., & Wierzbicki, A. S. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.21 · Cited by 34 · see citing works

Novel therapies and new targets of treatment for familial hypercholesterolemia

Goldberg, A. C. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.015 · Cited by 33 · see citing works

Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options

Anagnostis, P. G., Karras, S. Ν., Lambrinoudaki, I. V., Stevenson, J. C., & Goulis, D. G. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12903 · Cited by 34 · see citing works

Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion

Youssef, A., Clark, J. R., Marcovina, S. M., Boffa, M. B., & Koschinsky, M. L. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317335 · Cited by 33 · see citing works

Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia

Walsh, M. T., & Hussain, M. M. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2016.1221883 · Cited by 32 · see citing works

Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia

Vuorio, A. F., Tikkanen, M. J., & Kovanen, P. T. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s36641 · Cited by 32 · see citing works

Microsomal transfer protein (MTP) inhibition—a novel approach to the treatment of homozygous hypercholesterolemia

Sirtori, C. R., Pavanello, C., & Bertolini, S. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.931100 · Cited by 31 · see citing works

Lipoprotein(a) in clinical practice: New perspectives from basic and translational science

Scipione, C. A., Koschinsky, M. L., & Boffa, M. B. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1415866 · Cited by 33 · see citing works

Lomitapide for the treatment of hypertriglyceridemia

Berberich, A. J., & Hegele, R. A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1254187 · Cited by 29 · see citing works

Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease

Stein, E. A., & Raal, F. J. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6654-5 · Cited by 28 · see citing works

Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol

Badia, L. A. D., Elshourbagy, N. A., & Mousa, S. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.011 · Cited by 28 · see citing works

Lipoprotein(a)

Koschinsky, M. L., & Boffa, M. B. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.002 · Cited by 27 · see citing works

Emerging low-density lipoprotein therapies: Microsomal triglyceride transfer protein inhibitors

Goldberg, A. C. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.03.003 · Cited by 27 · see citing works

Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study

Poller, W. C., Berger, A., Dreger, H., Morgera, S., & Enke-Melzer, K. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.007 · Cited by 27 · see citing works

Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats

Dhote, V. V., Joharapurkar, A. A., Kshirsagar, S. G., Dhanesha, N., PATEL, V. G., Patel, A., Raval, S., & Jain, M. R. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05513.x · Cited by 27 · see citing works

New Therapeutic Approaches for Familial Hypercholesterolemia

Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 25 · see citing works

microRNA-30c reduces plasma cholesterol in homozygous familial hypercholesterolemic and type 2 diabetic mouse models

Irani, S., Iqbal, J., Antoni, W. J., Ijaz, L., & Hussain, M. M. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m081299 · Cited by 26 · see citing works

Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk

Noto, D., Cefalu, A. B., & Averna, M. R. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0414-4 · Cited by 25 · see citing works

Efficacy and Safety of Lomitapide in Hypercholesterolemia

Liu, X., Men, P., Wang, Y., Zhai, S., Zhao, Z., & Liu, C. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0214-7 · Cited by 26 · see citing works

Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia

Khoury, É., Brisson, D., Roy, N., Tremblay, G., & Gaudet, D. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602606 · Cited by 25 · see citing works

Severe familial hypercholesterolaemia: Current and future management

Farnier, M., & Bruckert, É. (2012) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2012.05.011 · Cited by 24 · see citing works

Inhibition of ApoCIII

Moens, S. J. B., van Capelleveen, J. C., & Stroes, E. S. G. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000130 · Cited by 24 · see citing works

New therapies to reduce low-density lipoprotein cholesterol

Wierzbicki, A. S., Viljoen, A., Hardman, T. C., & Mikhailidis, D. P. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283605fa2 · Cited by 24 · see citing works

Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus

Brouwers, M. C. G. J., Graaf, J. D., van Greevenbroek, M. M. J., Schaper, N. C., Stehouwer, C. D. A., & Stalenhoef, A. F. H. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ea9ec · Cited by 24 · see citing works

Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.

Rizzo, M. (2010) · PubMed · Cited by 27 · see citing works

Abstract 1500: Efficacy and Safety of the MTP-inhibitor, AEGR-733, as Monotherapy and in Combination with Ezetimibe

Samaha, F. F., McKenney, J. B., Bloedon, L. T., Sasiela, W. J., & Rader, D. J. (2006) · Circulation

AEGR 733,* a microsomal triglyceride transfer protein (MTP) inhibitor, may present a new avenue of cholesterol-lowering treatment,

&NA; (2007) · Inpharma Weekly · doi:10.2165/00128413-200716090-00015

Ezetimibe: a novel option for lowering cholesterol

Davidson, M. H. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.1.11 · Cited by 43 · see citing works

Ezetimibe: A First‐in‐Class, Novel Cholesterol Absorption Inhibitor

Lipka, L. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00123.x · Cited by 34 · see citing works